The Global Structural Biology and Molecular Modeling Market is expected to reach USD 18.1 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 17.1% from 2022 to 2028. The increased incidence of chronic diseases coupled with extensive Research and Development (R&D) activities in the drug discovery and development process is anticipated to augment the growth of the market during the forecast period.
- The SaaS & standalone modeling software segment held a significant share in 2021. This is attributable to the increasing number of computer-aided predictive procedures and their adoption by research professionals for analysis across the globe.
- The drug discovery segment is expected to grow at a considerable Compound Annual Growth Rate (CAGR) during the forecast period. This is owing to the increase in the benefits of molecular modeling in drug discovery. Additionally, in case of high clinical urgency in conditions, like pregnancy, where several drugs cannot be administered is also expected to support the segmental growth of the market.
- Asia Pacific is expected to grow at the fastest Compound Annual Growth Rate (CAGR) during the forecast period. This is attributable to the increasing healthcare IT spending in emerging economies like India, and China in the region. Furthermore, the increased presence of contract research organizations along with the evolution of the healthcare infrastructure is also anticipated to support the regional growth of the market.
Some of key players in Structural Biology and Molecular Modeling Market include Dassault Systèmes (France) , Agile Molecule , Acellera Ltd. (UK), ThermoFisher Scientific (US) , Agilent Technologies Inc (US) are the major companies operating in Structural Biology and Molecular Modeling Techniques Market..
The increasing development of drug discovery across the globe is expected to fuel the growth of the Structural Biology and Molecular Modeling Market in the years to come. This is owing to the rising healthcare expenditure and increasing occurrence of a varied range of chronic diseases like diabetes and cancer. Furthermore, the increasing prevalence of infectious disease and CNS disorders such as bacterial meningitis, stroke, epilepsy, and head injury is also expected to increase the demand for drug discovery in the years to come. However, the stringent regulations governing drug discovery and animal usage along with the shortage of skilled personnel are expected to hamper the growth of the market in the years to come. Moreover, growth in the drugs and biologics market despite the COVID-19 pandemic is further expected to augment the growth of the market within the forecast period. Additionally, the emergence of technological innovations in the development of validated mathematical models is also expected to fuel the growth of the market.
North America held the largest shares in 2021. This is attributable to the availability of advanced Research and Development (R&D) infrastructure and increased utilization of structural biology and molecular modeling in the region. Furthermore, the presence of pharmaceutical companies to conduct clinical trials is also augmenting the regional growth of the market. Additionally, increased ongoing research in biological sciences along with rising investments by various biotechnology companies are also supporting the growth of the Structural Biology and Molecular Modeling Market in the region.